ArticleWorld journal of urology2026
Determining the smallest worthwhile difference of beta-3 agonist treatment for overactive bladder: a benefit-harm trade-off study.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors associated with patient preferences for statin therapy in primary prevention.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe smallest worthwhile difference (SWD) represents the minimal beneficial effect of an intervention that patients consider valuable when weighed against its burdens, including potential harms, costs, and inconveniences. We aimed to determine the SWD for overactive bladder (OAB) treatment with beta-3 agonists and to evaluate the impact of trust in physicians on the SWD.
methodsWe recruited participants with symptoms suggestive of OAB in February 2025 through a research crowdsourcing service. The SWD for beta-3 agonists was estimated as a patient-required improvement in response rate to lifestyle modifications after three months using a benefit-harm trade-off approach. Trust in physicians was measured using the five-item Wake Forest Physician Trust Scale.
resultsOf 630 respondents, 472 who had symptom-related distress but were medication-naïve were included. Of these, 261 (55%) did not consider beta-3 agonist treatment worthwhile even if it achieved a 100% response. For the 211 participants willing to consider beta-3 agonists, the median SWD was a 20% improvement in response rate, with a wide interquartile range (5 to 40). In multivariable analysis, higher levels of trust in physicians were associated with smaller SWDs (mean difference per standard deviation, -4.11; 95% confidence interval, -7.00 to -1.22).
conclusionsMore than half of participants with symptoms suggestive of OAB and associated distress did not consider that beta-3 agonist treatment would be worthwhile given its burdens, even if there was a 100% response. Even among those willing to consider beta-3 agonists, the SWD varied substantially between individuals. Trust in physicians may influence SWD. RUNNING HEAD: Smallest Worthwhile Difference of Beta-3 Agonists for Overactive Bladder.
Indexed as
Identifiers
41697417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.